

# Ting-Bo Liang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7249316/publications.pdf>

Version: 2024-02-01

174  
papers

9,843  
citations

53794

45  
h-index

45317

90  
g-index

184  
all docs

184  
docs citations

184  
times ranked

17593  
citing authors

#	ARTICLE	IF	CITATIONS
1	Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny. <i>Gut</i> , 2022, 71, 1176-1191.	12.1	52
2	Impact of enhanced recovery protocols after pancreatoduodenectomy: meta-analysis. <i>British Journal of Surgery</i> , 2022, 109, 256-266.	0.3	19
3	Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients. <i>Journal of Translational Medicine</i> , 2022, 20, 49.	4.4	9
4	Randomized phase III study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: The CISPD3 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 560-560.	1.6	9
5	Randomized phase II trial of neoadjuvant chemotherapy with modified FOLFIRINOX versus modified FOLFIRINOX and PD-1 antibody for borderline resectable and locally advanced pancreatic cancer (the Tj ETQq1 1 01784314 rgt /Overd	1.6	9
6	Glutamine synthetase licenses APC/C-mediated mitotic progression to drive cell growth. <i>Nature Metabolism</i> , 2022, 4, 239-253.	11.9	13
7	One shoot, three birds: Targeting NEK2 orchestrates chemoradiotherapy, targeted therapy, and immunotherapy in cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, , 188696.	7.4	8
8	Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 56.	8.6	20
9	Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, 85.	9.1	11
10	Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. <i>BMC Cancer</i> , 2022, 22, 293.	2.6	18
11	Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors. , 2022, 10, e003982.		25
12	Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. , 2022, 10, e004129.		11
13	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 227-252.	1.5	55
14	Subtyping for pancreatic cancer precision therapy. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 482-494.	8.7	14
15	Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. <i>EBioMedicine</i> , 2022, 78, 103958.	6.1	15
16	Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 862154.	2.8	7
17	Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy. <i>EBioMedicine</i> , 2022, 79, 103987.	6.1	9
18	A non-canonical cGASâ€“STINGâ€“PERK pathway facilitates the translational program critical for senescence and organ fibrosis. <i>Nature Cell Biology</i> , 2022, 24, 766-782.	10.3	84

#	ARTICLE	IF	CITATIONS
19	Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. <i>Cancer Letters</i> , 2022, 539, 215722.	7.2	12
20	Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes. <i>Science Advances</i> , 2022, 8, .	10.3	15
21	Abstract CT546: A phase 2, multicenter study to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in patients with HCC at high risk of recurrence after curative resection. <i>Cancer Research</i> , 2022, 82, CT546-CT546.	0.9	0
22	RCAN1-mediated calcineurin inhibition as a target for cancer therapy. <i>Molecular Medicine</i> , 2022, 28, .	4.4	3
23	<i>FAT1</i> mutations in colorectal cancer patients are associated with the therapeutic benefit of immunotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, e15523-e15523.	1.6	0
24	Preliminary data of a prospective study on the safety and efficacy of donafinib combined with anti-PD-1 antibody as adjuvant therapy for patients with hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2022, 40, e16131-e16131.	1.6	3
25	mRNA vaccine development for cholangiocarcinoma: a precise pipeline. <i>Military Medical Research</i> , 2022, 9, .	3.4	6
26	Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity. , 2022, 10, e005065.		6
27	Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 157, 105631.	4.0	141
28	Practice Patterns and Perioperative Outcomes of Laparoscopic Pancreaticoduodenectomy in China. <i>Annals of Surgery</i> , 2021, 273, 145-153.	4.2	98
29	The Evolving Landscape of Noncanonical Functions of Metabolic Enzymes in Cancer and Other Pathologies. <i>Cell Metabolism</i> , 2021, 33, 33-50.	16.2	93
30	Preoperative transarterial chemoembolization for barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the milan criteria: a propensity score matching analysis. <i>Hpb</i> , 2021, 23, 1427-1438.	0.3	6
31	The protein phosphatase PPM1A dephosphorylates and activates YAP to govern mammalian intestinal and liver regeneration. <i>PLoS Biology</i> , 2021, 19, e3001122.	5.6	13
32	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 72.	17.1	191
33	A preoperative nomogram predicts prognosis of patients with hepatocellular carcinoma after liver transplantation: a multicenter retrospective study. <i>BMC Cancer</i> , 2021, 21, 280.	2.6	4
34	Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. <i>Molecular Cancer</i> , 2021, 20, 50.	19.2	83
35	Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. <i>Molecular Cancer</i> , 2021, 20, 44.	19.2	93
36	Fate mapping analysis reveals a novel murine dermal migratory Langerhans-like cell population. <i>ELife</i> , 2021, 10, .	6.0	18

#	ARTICLE	IF	CITATIONS
37	Group 2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2-Neutrophil-Induced Immunosuppression. <i>Hepatology</i> , 2021, 74, 2526-2543.	7.3	53
38	Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. <i>Oncogene</i> , 2021, 40, 3136-3151.	5.9	9
39	Pancreatic tumor initiation: the potential role of IL-33. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 204.	17.1	5
40	Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 4088-4088.	1.6	11
41	Glucose Metabolism: The Metabolic Signature of Tumor Associated Macrophage. <i>Frontiers in Immunology</i> , 2021, 12, 702580.	4.8	27
42	Vascular reconstruction of segmental intestinal grafts using autologous internal iliac vessels. <i>Gastroenterology Report</i> , 2021, 9, 350-356.	1.3	1
43	Cancer environmental immunotherapy: starving tumor cell to death by targeting TGFB on immune cell. <i>Frontiers in Immunology</i> , 2021, 9, e002823.		8
44	Gallbladder Adenosquamous Cancer with Situs Inversus Totalis: A Case Report and Literature Review. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4299-4304.	2.0	1
45	NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. <i>Nature Communications</i> , 2021, 12, 4536.	12.8	51
46	Cross-neutralization of RBD mutant strains of SARS-CoV-2 by convalescent patient derived antibodies. <i>Biotechnology Journal</i> , 2021, 16, e2100207.	3.5	8
47	Induced phase separation of mutant NF2 imprisons the cGAS-STING machinery to abrogate antitumor immunity. <i>Molecular Cell</i> , 2021, 81, 4147-4164.e7.	9.7	51
48	Non-cytoplasmic PD-L1: An atypical target for cancer. <i>Pharmacological Research</i> , 2021, 170, 105741.	7.1	19
49	A Seven-Gene Signature to Predict Prognosis of Patients With Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 728476.	2.3	5
50	Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 279.	8.6	31
51	Fully end-to-end deep-learning-based diagnosis of pancreatic tumors. <i>Theranostics</i> , 2021, 11, 1982-1990.	10.0	54
52	Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Review of Their Genetic Characteristics and Mouse Models. <i>Cancers</i> , 2021, 13, 5296.	3.7	6
53	Novel deep learning radiomics model for preoperative evaluation of hepatocellular carcinoma differentiation based on computed tomography data. <i>Clinical and Translational Medicine</i> , 2021, 11, e570.	4.0	11
54	Response to Comment on "Lung Transplantation for Elderly Patients With End-stage COVID-19 Pneumonia". <i>Annals of Surgery</i> , 2021, 274, e831.	4.2	1

#	ARTICLE	IF	CITATIONS
55	Immunosuppressants in Liver Transplant Recipients With Coronavirus Disease 2019: Capability or Catastrophe?—A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 756922.	2.6	7
56	The Cross Talk Between p53 and mTOR Pathways in Response to Physiological and Genotoxic Stresses. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 775507.	3.7	27
57	Multiplex imaging reveals the architecture of the tumor immune microenvironment. <i>Cancer Biology and Medicine</i> , 2021, 18, 949-954.	3.0	3
58	External validation of alternative fistula risk score (a-FRS) for predicting pancreatic fistula after pancreatoduodenectomy. <i>Hpb</i> , 2020, 22, 58-66.	0.3	28
59	Role of Collateral Venous Circulation in Prevention of Sinistral Portal Hypertension After Superior Mesenteric-Portal Vein Confluence Resection during Pancreaticoduodenectomy: a Single-Center Experience. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2054-2061.	1.7	6
60	Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget. <i>Cellular and Molecular Immunology</i> , 2020, 17, 677-679.	10.5	17
61	Reverting chemoresistance of targeted agents by a ultrasoluble dendritic nanocapsule. <i>Journal of Controlled Release</i> , 2020, 317, 67-77.	9.9	6
62	Liver Transplantation for Alcohol-Related Liver Disease (ARLD): An Update on Controversies and Considerations. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-6.	1.9	4
63	Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 1252.	3.5	2
64	CT Quantification and Machine-learning Models for Assessment of Disease Severity and Prognosis of COVID-19 Patients. <i>Academic Radiology</i> , 2020, 27, 1665-1678.	2.5	74
65	Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study. <i>Frontiers in Medicine</i> , 2020, 7, 347.	2.6	29
66	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. <i>Frontiers in Oncology</i> , 2020, 10, 590058.	2.8	5
67	Outcomes of liver transplantation using moderately steatotic liver from donation after cardiac death (DCD). <i>Annals of Translational Medicine</i> , 2020, 8, 1188-1188.	1.7	6
68	Evaluation of Intra-Tumoral Vascularization in Hepatocellular Carcinomas. <i>Frontiers in Medicine</i> , 2020, 7, 584250.	2.6	16
69	Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity. <i>Frontiers in Oncology</i> , 2020, 10, 1289.	2.8	4
70	Oncolytic virus combined with traditional treatment versus traditional treatment alone in patients with cancer: a meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1901-1913.	2.2	6
71	The AKT-independent MET—V-ATPase—MTOR axis suppresses liver cancer vaccination. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 122.	17.1	9
72	Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 138.	17.1	148

#	ARTICLE	IF	CITATIONS
73	Perioperative mental evaluation and intervention for lung transplantation in elderly patients with COVID-19. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 568-569.	1.8	2
74	Reviving the role of MET in liver cancer therapy and vaccination: an autophagic perspective. <i>OncolImmunology</i> , 2020, 9, 1818438.	4.6	7
75	Tumor-triggered personalized microRNA cocktail therapy for hepatocellular carcinoma. <i>Biomaterials Science</i> , 2020, 8, 6579-6591.	5.4	14
76	Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression. <i>Frontiers in Immunology</i> , 2020, 11, 2076.	4.8	17
77	Sphincter of Oddi laxity alters bile duct microbiota and contributes to the recurrence of choledocholithiasis. <i>Annals of Translational Medicine</i> , 2020, 8, 1383-1383.	1.7	14
78	Combinational therapy targeting the MET-mTOR-CROS loop disrupts mitochondrial autoregulatory machinery of liver cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e237.	4.0	3
79	Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. <i>Npj Precision Oncology</i> , 2020, 4, 29.	5.4	11
80	TBK1-Mediated DRP1 Targeting Confers Nucleic Acid Sensing to Reprogram Mitochondrial Dynamics and Physiology. <i>Molecular Cell</i> , 2020, 80, 810-827.e7.	9.7	35
81	Molecular Profiling-Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges. <i>Frontiers in Oncology</i> , 2020, 10, 532403.	2.8	20
82	Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 564-574.	3.4	68
83	Decreased B Cells on Admission Associated With Prolonged Viral RNA Shedding From the Respiratory Tract in Coronavirus Disease 2019: A Case-Control Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 367-371.	4.0	41
84	Construction of a human cell landscape at single-cell level. <i>Nature</i> , 2020, 581, 303-309.	27.8	695
85	Calreticulin couples with immune checkpoints in pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, 36-44.	4.0	15
86	Eating self for not be eaten: Pancreatic cancer suppresses self-immunogenicity by autophagy-mediated MHC-I degradation. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 94.	17.1	11
87	Contrast-enhanced CT radiomics for preoperative evaluation of microvascular invasion in hepatocellular carcinoma: A two-center study. <i>Clinical and Translational Medicine</i> , 2020, 10, e111.	4.0	53
88	Virus strain from a mild COVID-19 patient in Hangzhou represents a new trend in SARS-CoV-2 evolution potentially related to Furin cleavage site. <i>Emerging Microbes and Infections</i> , 2020, 9, 1474-1488.	6.5	51
89	piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis. <i>Nature Cell Biology</i> , 2020, 22, 425-438.	10.3	49
90	Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 152.	3.7	46

#	ARTICLE	IF	CITATIONS
91	Oncolytic virotherapy in hepatoâ€bilioâ€pancreatic cancer: The key to breaking the log jam?. <i>Cancer Medicine</i> , 2020, 9, 2943-2959.	2.8	12
92	A Deep Learning System to Screen Novel Coronavirus Disease 2019 Pneumonia. <i>Engineering</i> , 2020, 6, 1122-1129.	6.7	858
93	VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 83.	17.0	118
94	Genomeâ€wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. <i>Molecular Oncology</i> , 2020, 14, 1966-1977.	4.6	12
95	A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. <i>Hpb</i> , 2020, 22, 795-808.	0.3	39
96	Carcinosarcoma of the pancreas: comprehensive clinicopathological and molecular characterization. <i>Hpb</i> , 2020, 22, 1590-1595.	0.3	7
97	Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 485-492.	1.1	12
98	The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. <i>Nature</i> , 2020, 580, 530-535.	27.8	171
99	Contingency management strategies of the Nursing Department in centralized rescue of patients with coronavirus disease 2019. <i>International Journal of Nursing Sciences</i> , 2020, 7, 139-142.	1.3	28
100	Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. <i>BMJ, The</i> , 2020, 369, m1443.	6.0	1,226
101	Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. <i>Hpb</i> , 2020, 22, 821-832.	0.3	54
102	Recent controversies in liver transplantation. <i>Journal of Patan Academy of Health Sciences</i> , 2020, 7, 98-102.	0.2	1
103	USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity. <i>Cancer Immunology Research</i> , 2019, 7, 1580-1590.	3.4	94
104	A PEGylated megamer-based microRNA delivery system activatable by stepwise microenvironment stimulation. <i>Chemical Communications</i> , 2019, 55, 9363-9366.	4.1	14
105	ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-16.	1.5	21
106	&lt;p&gt;Stereotactic body radiotherapy as the initial treatment for hepatocellular carcinoma with extensive inferior vena cava and atrium tumor thrombus&lt;p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5299-5303.	2.0	1
107	Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. <i>British Journal of Cancer</i> , 2019, 121, 786-795.	6.4	47
108	B7â€H5/<sc>CD</sc>28H is a coâ€stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma. <i>Cancer Science</i> , 2019, 110, 530-539.	3.9	24

#	ARTICLE	IF	CITATIONS
109	ALK phosphorylates SMAD4 on tyrosine to disable TGF- $\beta$ <sup>2</sup> tumour suppressor functions. <i>Nature Cell Biology</i> , 2019, 21, 179-189.	10.3	41
110	Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. <i>Gut</i> , 2019, 68, 2019-2031.	12.1	230
111	Surgical management and outcome of grade-C pancreatic fistulas after pancreaticoduodenectomy: A retrospective multicenter cohort study. <i>International Journal of Surgery</i> , 2019, 68, 27-34.	2.7	11
112	Liver Transplantation from Voluntary Organ Donor System in China: A Comparison between DBD and DCD Liver Transplants. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-7.	1.5	7
113	Dermatological Disorders following Liver Transplantation: An Update. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-9.	1.9	5
114	Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. <i>Cancer Letters</i> , 2019, 452, 237-243.	7.2	78
115	Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin. <i>Biomaterials</i> , 2019, 192, 590-600.	11.4	61
116	Association of Modified FOLFIRINOX Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. <i>Oncologist</i> , 2019, 24, 301.	3.7	21
117	Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 196-203.	4.1	61
118	Impact of national Human Development Index on liver cancer outcomes: Transition from 2008 to 2018. <i>World Journal of Gastroenterology</i> , 2019, 25, 4749-4763.	3.3	13
119	Development of a radiomics nomogram based on the CE-CT features to predict the survival of upfront resectable patients with pancreatic head cancer and suspected venous invasion.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15760-e15760.	1.6	0
120	Effect of ARK5 on the anti-tumour activity of OSI-027 via regulation of epithelial-mesenchymal transition in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15758-e15758.	1.6	0
121	Pancreatic cancer: Assessment of neoadjuvant chemotherapy outcome based on radiomics of pretreatment computed tomography.. <i>Journal of Global Oncology</i> , 2019, 5, 56-56.	0.5	0
122	Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 473-485.	0.0	4
123	Pancreas-preserving management of grade-C pancreatic fistula and a novel bridging technique for repeat pancreaticojejunostomy: An observational study. <i>International Journal of Surgery</i> , 2018, 52, 243-247.	2.7	9
124	Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. <i>Surgery</i> , 2018, 164, 1392.	1.9	0
125	Hypoxia-inducible factor-1 $\beta$ /interleukin-1 $\beta$ signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment. <i>Hepatology</i> , 2018, 67, 1872-1889.	7.3	216
126	Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway. <i>Journal of Biological Chemistry</i> , 2018, 293, 1178-1191.	3.4	45



#	ARTICLE	IF	CITATIONS
127	Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression. <i>World Journal of Gastroenterology</i> , 2018, 24, 3500-3512.	3.3	58
128	Esophageal neuroendocrine carcinoma complicated with unexpected hyperprolactin. <i>Medicine (United States)</i> , 2018, 97, e12219.	1.0	8
129	Associating liver partition and portal vein ligation versus 2-stage hepatectomy. <i>Medicine (United States)</i> , 2018, 97, e12219.	1.0	25
130	Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. <i>Radiation Oncology</i> , 2018, 13, 188.	2.7	67
131	Laparoscopic Spleen-Preserving Distal Pancreatectomy (LSPDP) with Preservation of Splenic Vessels: An Inferior-Posterior Approach. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	1.5	11
132	CD69 enhances immunosuppressive function of regulatory T-cells and attenuates colitis by prompting IL-10 production. <i>Cell Death and Disease</i> , 2018, 9, 905.	6.3	69
133	Primary tumor-derived exosomes facilitate metastasis by regulating adhesion of circulating tumor cells via SMAD3 in liver cancer. <i>Oncogene</i> , 2018, 37, 6105-6118.	5.9	119
134	Patients with pancreatic cystic neoplasms can benefit from management of multidisciplinary team: Experience from a Chinese academic center. <i>Pancreatology</i> , 2018, 18, 799-804.	1.1	8
135	USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy. <i>Cancer Letters</i> , 2018, 436, 129-138.	7.2	45
136	Liquid biopsy in pancreatic cancer: the beginning of a new era. <i>Oncotarget</i> , 2018, 9, 26900-26933.	1.8	47
137	Cutting Edge: Notch Signaling Promotes the Plasticity of Group-2 Innate Lymphoid Cells. <i>Journal of Immunology</i> , 2017, 198, 1798-1803.	0.8	115
138	Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. <i>Genes and Development</i> , 2017, 31, 247-259.	5.9	207
139	OSI-027 modulates acute graft-versus-host disease after liver transplantation in a rat model. <i>Liver Transplantation</i> , 2017, 23, 1186-1198.	2.4	3
140	A hospital-to-home evaluation of an enhanced recovery protocol for elective pancreaticoduodenectomy in China. <i>Medicine (United States)</i> , 2017, 96, e8206.	1.0	7
141	Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1. <i>Cancer Research</i> , 2017, 77, 4868-4880.	0.9	116
142	Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. <i>Cancer Medicine</i> , 2017, 6, 1552-1562.	2.8	19
143	Hypoxia-inducible factor-2 $\alpha$ promotes tumor progression and has crosstalk with Wnt/ $\beta$ -catenin signaling in pancreatic cancer. <i>Molecular Cancer</i> , 2017, 16, 119.	19.2	97
144	Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial location. <i>Radiation Oncology</i> , 2016, 11, 138.	2.7	11

#	ARTICLE	IF	CITATIONS
145	The implementation of an enhanced recovery after surgery (ERAS) program following pancreatic surgery in an academic medical center of China. <i>Pancreatology</i> , 2016, 16, 665-670.	1.1	31
146	ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-to-mesenchymal transition. <i>Cancer Letters</i> , 2016, 377, 140-148.	7.2	40
147	A redox-sensitive, oligopeptide-guided, self-assembling, and efficiency-enhanced (ROSE) system for functional delivery of microRNA therapeutics for treatment of hepatocellular carcinoma. <i>Biomaterials</i> , 2016, 104, 192-200.	11.4	37
148	Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent. <i>Scientific Reports</i> , 2016, 6, 23269.	3.3	90
149	G protein-coupled estrogen receptor deficiency accelerates liver tumorigenesis by enhancing inflammation and fibrosis. <i>Cancer Letters</i> , 2016, 382, 195-202.	7.2	47
150	Meta-analysis of invagination and duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: An update. <i>International Journal of Surgery</i> , 2016, 36, 240-247.	2.7	25
151	The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway. <i>Cancer Letters</i> , 2016, 380, 98-105.	7.2	38
152	Duct-to-Mucosa vs Invagination for Pancreaticojejunostomy after Pancreaticoduodenectomy: A Prospective, Randomized Controlled Trial from a Single Surgeon. <i>Journal of the American College of Surgeons</i> , 2016, 222, 10-18.	0.5	78
153	One-stage laproendoscopic procedure versus two-stage procedure in the management for gallstone disease and biliary duct calculi: a systemic review and meta-analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 3582-3590.	2.4	47
154	Roles of Sphincter of Oddi Laxity in Bile Duct Microenvironment in Patients with Cholangiolithiasis: From the Perspective of the Microbiome and Metabolome. <i>Journal of the American College of Surgeons</i> , 2016, 222, 269-280e10.	0.5	31
155	Role of IL-21 signaling pathway in transplant-related biology. <i>Transplantation Reviews</i> , 2016, 30, 27-30.	2.9	13
156	Interplay between myeloid-derived suppressor cells (MDSCs) and Th17 cells: foe or friend?. <i>Oncotarget</i> , 2016, 7, 35490-35496.	1.8	20
157	Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors. <i>Scientific Reports</i> , 2015, 5, 13664.	3.3	49
158	Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the $\beta$ -catenin/TCF complex association via FOXO3a activation. <i>Oncotarget</i> , 2015, 6, 10350-10365.	1.8	84
159	AFP (alpha fetoprotein): Who are you in gastrology?. <i>Cancer Letters</i> , 2015, 357, 43-46.	7.2	34
160	WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation. <i>Cancer Letters</i> , 2015, 361, 218-225.	7.2	55
161	A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. <i>Cell Research</i> , 2015, 25, 997-1012.	12.0	84
162	OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2015, 6, 26230-26241.	1.8	18

#	ARTICLE	IF	CITATIONS
163	A Case Report on Successful Liver Transplantation from a Donor with Polycystic Liver. <i>Indian Journal of Surgery</i> , 2014, 76, 405-407.	0.3	0
164	Hepatic RIG-I Predicts Survival and Interferon- $\gamma$ Therapeutic Response in Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2014, 25, 49-63.	16.8	182
165	Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1 $\alpha$ -VEGF mediated angiogenesis. <i>Cancer Letters</i> , 2014, 355, 281-287.	7.2	44
166	Surgical resection and outcome of pancreatic cystic neoplasms in China: analysis of a 16-year experience from a single high-volume academic institution. <i>World Journal of Surgical Oncology</i> , 2014, 12, 228.	1.9	9
167	Wnt/ $\beta$ -catenin signaling enhances hypoxia-induced epithelial $\rightarrow$ mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1 $\alpha$ signaling. <i>Carcinogenesis</i> , 2013, 34, 962-973.	2.8	208
168	Macrophage-Induced Tumor Angiogenesis Is Regulated by the TSC2 $\rightarrow$ mTOR Pathway. <i>Cancer Research</i> , 2012, 72, 1363-1372.	0.9	154
169	Mesenchymal stem cells administered after liver transplantation prevent acute graft-versus-host disease in rats. <i>Liver Transplantation</i> , 2012, 18, 696-706.	2.4	30
170	Rapamycin and tacrolimus differentially modulate acute graft-versus-host disease in rats after liver transplantation. <i>Liver Transplantation</i> , 2010, 16, 357-363.	2.4	15
171	Regulatory T cells contribute to the immunoregulatory effect on graft versus host reaction after liver transplantation in donor-dominant one-way MHC matching rats. <i>Transplant Immunology</i> , 2009, 20, 232-237.	1.2	7
172	Liver Transplantation for Hepatocellular Carcinoma: Hangzhou Experiences. <i>Transplantation</i> , 2008, 85, 1726-1732.	1.0	400
173	Activation pattern of mitogen-activated protein kinases in early phase of different size liver isografts in rats. <i>Liver Transplantation</i> , 2005, 11, 1527-1532.	2.4	46
174	Acute Decompensated Liver: When to Transplant?. , 0, , .		1